Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Precancerous Conditions 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Sarcoma 1Salivary Gland Neoplasms 1Papillomavirus Infections 1Multi-centric Castleman's Disease 1Lymphoma 1HIV Infections 1Disease 1Breast Neoplasms 1AIDS-related Kaposi sarcoma 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 166Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 84Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × Histological Techniques × Clear all
NCT01668914 2018-04-05

IMSLNB-CANP

Shandong Cancer Hospital and Institute

Phase 3 Completed
126 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡